GoalVest Advisory LLC Acquires 2,207 Shares of Kenvue Inc. $KVUE

GoalVest Advisory LLC boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 104,023 shares of the company’s stock after acquiring an additional 2,207 shares during the period. GoalVest Advisory LLC’s holdings in Kenvue were worth $2,177,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of KVUE. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue in the first quarter valued at about $30,000. Trust Co. of Vermont lifted its holdings in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the first quarter valued at about $36,000. Truvestments Capital LLC bought a new stake in shares of Kenvue in the first quarter valued at about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Kenvue by 378.5% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after purchasing an additional 1,287 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

KVUE opened at $15.00 on Monday. Kenvue Inc. has a 52-week low of $14.05 and a 52-week high of $25.17. The firm has a market capitalization of $28.78 billion, a PE ratio of 20.26, a PEG ratio of 2.16 and a beta of 0.72. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The business’s 50-day simple moving average is $17.91 and its 200 day simple moving average is $20.79.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.Kenvue’s revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 27th. Shareholders of record on Wednesday, August 13th were paid a $0.2075 dividend. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 5.5%. The ex-dividend date was Wednesday, August 13th. Kenvue’s dividend payout ratio is currently 112.16%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KVUE. Evercore ISI cut their price target on Kenvue from $23.00 to $18.00 and set an “in-line” rating on the stock in a report on Tuesday, September 23rd. Zacks Research upgraded Kenvue to a “strong sell” rating in a report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Canaccord Genuity Group dropped their target price on Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Finally, Royal Bank Of Canada dropped their target price on Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.